2-<2-(dimethylamino)ethyl>-5-<<(4-methylphenyl)sulfonyl>oxy>indazolo<4,3-gh>isoquinolin-6(2H)-one | 156090-03-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-<2-(dimethylamino)ethyl>-5-<<(4-methylphenyl)sulfonyl>oxy>indazolo<4,3-gh>isoquinolin-6(2H)-one
• 英文别名: 2-[2-(dimethylamino)ethyl]-5-(p-toluenesulfonyloxy) isoquino[8,7,6-cd]indazole-6(2H)-one；2-[2-(dimethylamino)ethyl]-5-(p-toluenesulfonyloxy)isoquino[8,7,6-cd]indazole-6(2H)-one；[14-[2-(dimethylamino)ethyl]-8-oxo-4,14,15-triazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-10-yl] 4-methylbenzenesulfonate
• CAS: 156090-03-8
• 化学式: C₂₄H₂₂N₄O₄S
• 分子量: 462.529
• InChiKey: BKYYMPOPHVTGJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  103
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-<2-(dimethylamino)ethyl>-5-<<(4-methylphenyl)sulfonyl>oxy>indazolo<4,3-gh>isoquinolin-6(2H)-one 在 吡啶 、 盐酸 作用下， 以 乙醇 为溶剂， 反应 23.0h， 生成 2-<2-(dimethylamino)ethyl>-5-<<2-(piperazin-1-yl)ethyl>amino>indazolo<4,3-gh>isoquinolin-6(2H)-one trihydrochloride
  参考文献：
  名称：

  Paul Krapcho, Journal of Medicinal Chemistry, 1998, vol. 41, # 27, p. 5429 - 5444

  摘要：

  DOI：
• 作为产物：
  描述：

  6,9-二氟苯并异喹啉-5,10-二酮 在 甲烷磺酸 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 2-<2-(dimethylamino)ethyl>-5-<<(4-methylphenyl)sulfonyl>oxy>indazolo<4,3-gh>isoquinolin-6(2H)-one
  参考文献：
  名称：

  Paul Krapcho, Journal of Medicinal Chemistry, 1998, vol. 41, # 27, p. 5429 - 5444

  摘要：

  DOI：

文献信息

• Hetero-annulated indazoles
  申请人：The University of Vermont

  公开号：US05596097A1

  公开（公告）日：1997-01-21

  This invention is directed to heteroannulated indazoles namely to 2,5-disubstituted quinolino-, isoquinolino-, phthalazino-, and quinoxalino- annulated indazole-6(2H)-ones and related mono N-oxides. These compounds have been shown to have antitumor activity.

  这项发明涉及杂环并联吲唑，特别是2,5-二取代喹啉基、异喹啉基、邻苯二氮杂环基和喹啉基并联的吲唑-6(2H)-酮及相关的单N-氧化物。这些化合物已被证明具有抗肿瘤活性。
• 2-aminoalkyl-5-aminoalkylamino substituted-isoquinoindazole-6(2H)-ones
  申请人：Boehringer Mannheim Italia SpA

  公开号：US05604246A1

  公开（公告）日：1997-02-18

  This invention is directed to 2-aminoalkyl-5-aminoalkylamino substituted isoquino[8,7,6-cd]indazole-6-(2H)-ones and to 2-aminoalkyl-5-aminoalkylamino substituted-isoquino[5,6,7-cd]indazole-6(2H)-ones. These compounds have been shown to have antitumor activity.

  本发明涉及2-氨基烷基-5-氨基烷基氨基取代的异喹啉[8,7,6-cd]吲哚-6-(2H)-酮和2-氨基烷基-5-氨基烷基氨基取代的异喹啉[5,6,7-cd]吲哚-6(2H)-酮。这些化合物已被证明具有抗肿瘤活性。
• Synthesis and Antitumor Evaluation of Bis Aza-anthracene-9,10-diones and Bis Aza-anthrapyrazole-6-ones
  作者：Ippolito Antonini、Giorgio Santoni、Roberta Lucciarini、Consuelo Amantini、Diego Dal Ben、Rosaria Volpini、Gloria Cristalli

  DOI：10.1021/jm7013937

  日期：2008.2.1

  The good results obtained as potential antitumor drugs with aza-anthracenediones and aza-anthrapyrazoles, e.g. pixantrone, 1a, and 1b (Chart 1), prompted us to design and synthesize a series of symmetrical bis derivatives, compounds 7-10 (Chart 1). These compounds are dimers of different aza-anthracenedione and aza-anthrapyrazolone monomers connected by the linker found to be the most appropriate among potential bis intercalators synthesized by us. The DNA-binding properties of bis derivatives 7 and 8 have been examined using fluorometric techniques: these target compounds are excellent DNA ligands, with a clear binding site preference for AT-rich duplexes. In vitro cytotoxic activity of all target compounds 7-10 and of reference compound pixantrone toward human cancer adenocarcinoma cell line HT29 is also described. Two selected compounds have been investigated for their capacity of inducing early apoptosis.
• 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY
  申请人：THE UNIVERSITY OF VERMONT

  公开号：EP0662076B1

  公开（公告）日：2001-04-11
• HETERO-ANNULATED INDAZOLES
  申请人：Novuspharma S.p.A.

  公开号：EP0750619B1

  公开（公告）日：2001-05-30